Premium
Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine
Author(s) -
Aquilonius S.M.,
Askmark H.,
Eckernäs S.Å.,
Gillberg P.G.,
HiltonBrown P.,
Rydin E.,
Stålberg E.
Publication year - 1986
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1986.tb04610.x
Subject(s) - neostigmine , physostigmine , amyotrophic lateral sclerosis , cholinesterase , medicine , anesthesia , pharmacology , acetylcholine , disease
Seven patients with amyotrophic lateral sclerosis participated in a doubleblind cross‐over trial of oral physostigmine and neostigmine (10 and 45 mg/day, respectively, for 3 days). Six of the patients were also given intravenous injections (1 and 1.5 mg, respectively) of the drugs in an open trial. No significant effects on muscle strength or neurophysiological parameters were observed.